Estimated at USD 67.50 billion in 2025, the Blood Cancer Drugs Market is projected to grow from USD 74.44 billion in 2026 to USD 164.04 billion by 2034, registering a CAGR of 10.4% during 2026–2034. North America dominated in 2025.

Rising incidence of hematological malignancies and longer treatment durations drive demand. Leukemia targeted therapies held the largest indication share (approximately 38% in 2025), supported by oral BTK and BCL-2 inhibitors that enable prolonged outpatient management. Lymphoma immunotherapy agents, including monoclonal antibodies and antibody-drug conjugates, accounted for roughly 34% of revenue.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market

Multiple myeloma treatment regimens (about 28% share) rely on multi-drug combinations and continuous therapy, generating high lifetime drug exposure. CAR-T cell therapies deliver deep responses in relapsed settings, while bispecific antibody platforms offer off-the-shelf alternatives that expand access. Key companies include AbbVie, Amgen, AstraZeneca, Bayer, Celgene, Eli Lilly, Roche, Johnson & Johnson, Merck, and Pfizer.

Precision medicine, earlier-line approvals, and sustained maintenance strategies underpin robust long-term growth.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market